Skip to main content
. 2023 Jul 28;5(4):e220126. doi: 10.1148/rycan.220126

Figure 1:

Schematic shows study protocol. Participants were randomly assigned to one of 10 neoadjuvant drug arms (nine experimental drug arms and one standard-of-care control arm). Each participant underwent MRI examination at four treatment time points (T0, T1, T2, T3) during neoadjuvant chemotherapy. FTV0, FTV1, FTV2 = functional tumor volume at T0, T1, and T2, respectively; ΔFTV1, ΔFTV2 = percentage change of functional tumor volume relative to T0 at T1 and T2, respectively.

Schematic shows study protocol. Participants were randomly assigned to one of 10 neoadjuvant drug arms (nine experimental drug arms and one standard-of-care control arm). Each participant underwent MRI examination at four treatment time points (T0, T1, T2, T3) during neoadjuvant chemotherapy. FTV0, FTV1, FTV2 = functional tumor volume at T0, T1, and T2, respectively; ΔFTV1, ΔFTV2 = percentage change of functional tumor volume relative to T0 at T1 and T2, respectively.